ecrin-mdr-crcClinical2023IPD Sharing (as of August 2023): NoColorectal NeoplasmsMSI-H Colorectal CancerColorectal NeoplasmsMsi-h Colorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/71370United States8PembrolizumabImmune checkpoint inhibitorVascular endothelial growth factor receptor (VEGFR)Multi-kinase inhibitorReceptor tyrosine kinasesAnti-PD1 blockadeECRIN MDRNot yet recruitingfalseRegorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal CancerThis is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine efficacy.2023-08-1571370NCT06006923